`
`FOOD AND DRUG ADMINIS,RATION
`
`CENTER FOR DRUG ~VALUATION AND RESEARCH
`
`1
`
`PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS
`
`ADVISORY COMMITTEE
`
`Wednesday, June 6, 2001
`
`8:15a.m.
`
`Ho:iday Inn
`Bethesda, Maryland
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 1 of 400
`
`
`
`2
`
`PART::LCIPANTS
`
`Claudia H. Kawas, M.D., Cor.sultar.t and Actir..g
`Chairman
`Sandra Titus, Ph.D., Executive Secreta~-:y
`
`MEMBERS:
`
`Ella P. Lacey, ?h.J., Consumer Rep~esentative,
`LaRoy P. Penix, M.D.
`Richard D. Penn, M.D.
`Gerald Van Belle, Ph.D.
`
`CONSTJLTII.NTS:
`
`Gustavo C. Roman, M.D.
`Jerry S. Wolinsky M.D.
`
`XYREM CONSU!,TA..'JTS:
`
`VOTING:
`
`Pippa Simpson, Ph.D.
`Carol Falkowski, Ph.D.
`
`NON-VOTING:
`
`Christine A. Sannerud, Ph.D.
`Jerry Frankenhcim, Ph.D.
`Jo-Ellen Dyer, Ph.D.
`
`ON PONE-LINK - NON-VOTING:
`
`Ronald Chervin, M.D.
`Christian Guilleminault, M.D.
`
`FDA:
`
`Robert Temple, M.D.
`Russell Kat=, M.D.
`Ranjit Mani, M.D.
`Jo~n Feeney, M.D.
`Deborah R. Leidcrman, M.D.
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 2 of 400
`
`
`
`C 0 N T E N 7 S
`
`Call to Order and Introductions
`
`Conflict of Interest
`
`FDA Overview, Russell Katz, M.D.
`
`Orphan Medical Presentation:
`Introduction, David Reardan, Ph.D.
`Medical Need, Emmanuel Mignot, M.D.
`Efficacy, William Houghton, M.D.
`Polysomnographic Effects of Xyrem, Jed Black, M.D.
`Safety and Summary of Risk/Benefit Assessment,
`William Houghton, M.D.
`
`FDA Response to the Presentation, Ranjit Mani, M.D.
`Committee Discussion and Deliberations
`
`FDA Invited Speakers on Risk Management. Issues:
`Epidemiology of GHB Abuse Issues,
`Carol Falkowski
`Adverse Medical Effects with GHB,
`Jo Ellen Dyer
`
`Sponsor Pn~sentation on Risk Managem~nt. and Abuse
`Liability, Bob Balster, Ph.D.
`162
`Risk Management, Patti Engel, R.N., BSN
`
`Open Public Hearing:
`
`Sharon Fitzgerald, Littleton, Colorado
`Richard T... Gelulla, MSW, National Sleep
`Foundation
`AbbeyS. Meyers, National Organizat:ion
`for Rare Disorders, Inc.
`Robert L. Clo'...ld, Narcolepsy Network
`Cindy Pek-3-rick
`Eric C. Strain, M.D., College on Problems of
`Drug Dependence
`Deborah Zvorsec, Ph.D., Her..nepin Cnur:ty
`Medical Center
`Trinka Porrata, LAPD
`Matt Speakman
`Charles F. Cichon, National As so:::\ i::lt.:!.or.. of Drug
`Diversion Investigators
`Debbie A~umba'...lgh, Michael's ~essage
`Foundation, Inc.
`Brian A. Hunter, Young Adults with ~arcolepsy
`Joe Spillane, Pbarm.D., ABAT
`r-1ali Einen
`Sand1: a Jon.:-:s
`
`Continued Committee Discussion u.nd DeliDcrat.ions
`
`3
`
`4
`
`G
`
`8
`
`19
`25
`36
`55
`
`61
`
`84
`89
`
`131
`
`148
`
`176
`
`187
`
`191
`
`197
`200
`20~
`
`208
`
`213
`218
`223
`
`227
`
`230
`~3"3
`237
`241
`246
`
`2·19
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 3 of 400
`
`
`
`4
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`P R 0 C R E D I N G S
`
`Call to Order and Ir.t~·od'J.ctions
`
`DR. KAWAS: Good morning, everyone, and
`
`welcome to the Wednesday, June 6, 2001 meeting of
`
`the Peripheral and Central Nervous Sy£;tem Advisory
`
`Committee. My name is Claudia Kawus, and I think
`
`we can begin with introductions, please, perhaps
`
`over by Dr. Temple•s side.
`
`DR. TEMPLE: Bob Temple,
`
`I am the Office
`
`Di~·ector.
`
`DR. KATZ: Russ Katz, Division of
`
`12 Neuropharmacological Drug P~·oducts, FDA.
`
`13
`
`14
`
`15
`
`DR. FEENEY:
`
`John Feeney, neurology team
`
`leader, FDA.
`
`DR. MANI: Ranjit Mani, medical reviewer,
`
`16
`
`Neurophi:irm., FDA.
`
`17
`
`DR. LEI DERMAN: Deborah ~.eiderman,
`
`18 Director, Controlled Substance Staff, FDA.
`
`19
`
`DR. SIMPSON: Pippa Simpson, University of
`
`20 Arkansas Medical Sciences, biostatistician.
`
`21
`
`22
`
`23
`
`DR. FALKOWSKI: Carol Falkowski, drug
`
`abuse researcher, Hazelden Foundation.
`
`DR. ROMAN: Gustavo Romar:., Professor of
`
`24 Neurology at the University of Texas, San Antonio.
`
`25
`
`DR. WOLINSKY:
`
`Jerry Wolinsky, Professor
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 4 of 400
`
`
`
`5
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`of Neurology, Unive~·sity of Lexas, nouston.
`
`DR. TITUS' Sandy Titus, FDA, the
`
`administ~ator of the Peripheral ar.d Central Nervous
`
`System Committee.
`
`DR. PENN:
`
`Richa~d Penn, neurosurgeon at
`
`the University of Chicago.
`
`DR. LACEY: Ella Lacey, p~ofessor emerita,
`
`Illinois University, Carbondale, Tllinois.
`
`DR. VAN BELLE, Gerald Van Belle,
`
`10 Department of Biostatistics, from the University of
`
`11 Washington.
`
`12
`
`DR. PENIX: LaRoy Penix, Associate
`
`13
`
`Professor of Neurology at Moorehouf.;e School of
`
`14 Medicine.
`
`15
`
`16
`
`17
`
`18
`
`DR. SANNERUD: Christina Sannerud, Drug
`
`and Chemical Evaluation Section, D-::-ug Enforcement
`
`Administ~ation.
`
`DR. DYER,
`
`I am Jo Dyer, with the
`
`19 University of California, San Francisco and the San
`
`20
`
`21
`
`22
`
`23
`
`24
`
`Francisco Poison Control System, Ca~ifornia.
`
`DR. FRANKENHEIM:
`
`Jerry Frankenheim,
`
`pharmacologist, National Institute on Drug Abuse.
`
`DR. Y.AWAS; Today we have met to discuss
`
`the conside;.ation of Xyrem, proposed to reduce the
`
`25
`
`incidence of cataplexy and to imp:ove the symptom
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 5 of 400
`
`
`
`6
`
`l
`
`of daytime sleepiness for persons with narcolepsy.
`
`The main focus of the deliberutions will also be on
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`risk management issues.
`
`If we could ask Dr. Titus to begin with
`
`the conflict of interest statement?
`
`Conflict of Interest Statement
`
`DR. TITUS: Before I begin the conflict of
`
`interest statement, I just wunt to announce that we
`
`have two people on line with us, Dr. Chervin and
`
`10 Dr. Guilleminault. They are both in a room
`
`11
`
`listening to us and will participate with us on the
`
`12 mikes.
`
`13
`
`14
`
`The following announcement addresses the
`
`issue of conflict of interest with regard to this
`
`15 meeting and is made a part of the record to
`
`16
`
`preclude even the appearance of such at this
`
`17 meeting.
`
`18
`
`19
`
`The special government employees
`
`participating in today's meeting have been screened
`
`20
`
`for interests in Orphan Medical's Xyrem and for
`
`21
`
`22
`
`23
`
`24
`
`interests in the products and sponsors deemed by
`
`the agency to be competing. Bused on the agency's
`
`review of each participant's response to the
`
`conflict of interest screening, it has been
`
`25
`
`determined that there is no potential for a
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 6 of 400
`
`
`
`7
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`conflict of ir.terest with regayd to this meeting.
`
`With respect to FDA 1 s invited guests,
`
`there are reported affiliations which we believe
`
`should be made public to allow the participants to
`
`objectively evaluate their. comments.
`
`Dr. Ronald Chervin would like to disc:ose
`
`fo~- the record that he has a contract with Cephalon
`
`to study Provigil, but not for use in narcolepsy.
`
`He is the principal investigator, however, no funds
`
`from Cephalon, present or past, have contributed to
`
`his personal salary and none have been made
`
`12
`
`available for his non-research related use.
`
`13
`
`14
`
`15
`
`16
`
`Further, in previous years Dr. Chervin was a
`
`co··investigator with Cephalon in a narcolepsy
`
`clinical trial.
`
`Christian Guillemin.ault has been the
`
`17
`
`administrator of the Sleep Disorder Clinic in Palo
`
`18 Alto, California, where the study of Xyrem was
`
`19
`
`performed by a team of researchers.
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`In the event that the discussions involve
`
`any other products or firms not already on the
`
`agenda for which an FDA participant has a financia:
`
`inter.est, the partici.pants ar-e aware of the: need to
`
`exclude themselves f~om such involvement and their
`
`exclusion will be noted for the- ~ecord.
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 7 of 400
`
`
`
`8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`With respect to all other participants, we
`
`ask in the interest of fairness thut tney add:ess
`
`any current or previous involvement with any fi:!:"m
`
`whose products they may wish to comment upon.
`
`Thank you.
`
`DR. KAWAS: Thank you very much, Dr.
`
`Titus. We will begin with D~. Russell Katz, of the
`
`FDA, who will give us the FDA overview of the
`
`issues.
`
`I want to point out to the committee
`
`10 members that they have much of the materials that
`
`11
`
`12
`
`13
`
`14
`
`they will be seeing during this meeting in front of
`
`them.
`
`FDA Overview
`
`DR. KATZ: Thanks, Claudia. First, I
`
`15 would like to welcome the committee back. You we~e
`
`16
`
`here just a few months ago so I appreciate your
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`coming back so soon.
`
`We have a number of invited guests who arc
`
`augmenting the committee today, and many of them
`
`are experts in the evaluation of issues related to
`
`d:-ug abuse, and I would just like to welcome them,
`
`in particular Drs. Simpson, Sannerud and
`
`Frankenheim.
`
`We have two other experts who will
`
`actually be speakers later this morning. Dr. Dyer
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 8 of 400
`
`
`
`9
`
`1 will speak on her e::-:pe1.·ience wi t!-1 GMB use and
`
`2 misuse in cases she has seen, and Dr. Falkowski
`
`3 will talk about the epidemiology of GHB abuse in
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`the United States.
`
`Fir.ally, as Dr. Titus mentioned, we have
`
`two acknowledged experts in sleep disorders who are
`
`attending the annual sleep meetings in Chicago, but
`
`who have agreed to sit in a hotel room for howeve~-
`
`long this takes and participate by phone. So, Drs.
`
`10 Guilleminault and Chervin, whereve~- you are, thank
`
`11
`
`12
`
`you. Thanks for being here.
`
`As you know and as you have heard, today
`
`13
`
`we will ask you to discuss NDA 21-196, which was
`
`14
`
`submitted by Orphan Medical for the use of Xyrem,
`
`15
`
`gamma hydroxybutyrate or better known as GHB, for
`
`16
`
`the treatment of cataplexy and excessive daytime
`
`17
`
`sleepiness in patients with narcolepsy.
`
`18
`
`19
`
`20
`
`21
`
`7.2
`
`GHB is a simple molecule and it is
`
`ubiquitous in mammalian tissues, its function
`
`though is not really well known.
`
`Its relevant
`
`regulatory history goes back to about 1990, and
`
`prior to that date it was freely available in
`
`23
`
`':1ealth food stores. But in 1990 tf:.e agency began
`
`L4
`
`25
`
`to receive reports of widespyead recreational use
`
`in a number of different types of folks, for a
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 9 of 400
`
`
`
`10
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`number of different types of reasons, or GH3 and
`
`began to get numerous reports of serious adverse
`
`events associated with its misuse.
`
`It was not entirely clear that all of
`
`these events were necessarily related to GHB.
`
`It.
`
`was difficult to interpret some of these reports
`
`because there were concomitant medications that
`
`were unreported and it wasn't entirely clear
`
`9 whether or how much GHB was in a particular
`
`10
`
`preparation that someone had taken. Those scrt.s of
`
`11
`
`issues made it difficult to completely inte1·prt~t.
`
`12
`
`13
`
`14
`
`the reports, but many of the reports were of events
`
`that were known to be consistent with GHB's effect
`
`as a potent CNS depressant, including things like
`
`15
`
`respiratory depression, coma and other decreased
`
`16
`
`17
`
`18
`
`19
`
`levels of consciousness. So, it was reasonable t.rJ
`
`believe that GHB was at least in part respor.siblc
`
`for some of these reports.
`
`As a result of these reports, the agency
`
`20 withdrew GHB from health food shelves ar.d mude
`
`it.
`
`21
`
`22
`
`23
`
`24
`
`illegal to use. However, illicit use cont.inu<:!d and
`
`continues to this day, not only with GHB but with
`
`two related d~ugs which are precursors, GBL und
`
`1,4-butanediol, and there have been simila~ reports
`
`:~5
`
`of serious adverse events associated with the :lf;e
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 10 of 400
`
`
`
`I I
`
`l
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`of these products.
`
`So, against this backg~·ound of '...lse, the
`
`investigation of GHB as a treatme~t for cataplexy
`
`began. Based on the results of a single trial
`
`performed by the sponsor and their commitment. to
`
`perform additional trials, the sponsor was granted
`
`a treatment IND in December of 1998. For those of
`
`you unfamiliar with a treatment IND, it is
`
`basically a mechanism to permit use of an
`
`10
`
`investigational drug outside the context of a
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`controlled trial for a serious disease for which
`
`there aren't other available treatments.
`
`It is
`
`usually granted relatively late in the developme~t
`
`of a drug so that by the time you grant it ycu have
`
`some reasonable idea, based on controlled data,
`
`that the drug is probably effective and reasonably
`
`17 well tolerated.
`
`18
`
`19
`
`20
`
`21
`
`22
`
`:n
`
`24
`
`25
`
`Just anothe~ relevant piece of histo~y. in
`
`2000 Congress passed a law which placed GHB in
`
`Schedule I and also placed it into Schedule III for
`
`any approved uses that may be granted.
`
`The NDA that we are discussing today was
`
`submitted in September of 2000 by the company, und
`
`it contains the results of four controlled t~ials
`
`which the sponsor believes establish substantia~
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 11 of 400
`
`
`
`1::!
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`evidence of effectiveness for cataplexy and
`
`excessive daytime sleepiness in patier1ts wit~
`
`narcolepsy.
`
`It also contains, obviously, safety
`
`experience.
`
`T iust want to talk about the safety
`
`experience for just. a little bit. As you know from
`
`the briefing documents, much of the safety data in
`
`the application was not generated by the company
`
`but by an individual investigator under his own
`
`10
`
`individual invcstiqator IND. This is Dr. Scharf,
`
`11
`
`12
`
`13
`
`14
`
`and he is an acknowledged expert in the use of GHB
`
`and he has been treating patients under his IND for
`
`about 16 years. His data comprise almost 30
`
`percent of the patient safety database in the NDA.
`
`15
`
`If one looks at patient time, his experience
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`constitutes about 70 percent of the total patient
`
`exposure.
`
`As part of a routine investigutior.. of tt:.e
`
`NDA to look at. sou~-ce documents, the agency
`
`investigators found that they were unable to locate
`
`some critical source documents of Dr. Scharf 1 s IND,
`
`and it was diffic:1lt to confirm the sponsor 1 S
`
`submission of Dr. Scharf 1 S data. Ho~ever,
`
`subsequent to that, Dr. Scharf has made extensive
`
`efforts to p~·ovide the additional source documents
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 12 of 400
`
`
`
`13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`and ager.cy investigators have reinspected that
`
`data.
`
`I believe t:-te conclusion of that
`
`investigation is that we find that the records, for
`
`the most part, do support the spor.sor•s
`
`descriptions of Dr. Scharf's data. And, we believe
`
`we can make certain statements about that data at
`
`this point.
`
`We were particularly interested in the 80
`
`or so patients that Dr. Scharf treated that did not
`
`10
`
`move on into the company's treatment IND. He
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`treated a totul of 143, or thereabouts, patients,
`
`60 of whom went into the sponsor's treatment TND.
`
`So, we had a good idea of what was happening to
`
`those patients but there were about 80 that didn't
`
`and who were basically discontinued from treatment
`
`under Dr. Scharf's own IND.
`
`So, except for a handful of patients, we
`
`believe we know why those 80 patients discontinued
`
`and their status.
`
`I believe we can suy reasonably
`
`comfortably say that nothing catastrophic that we
`
`don't know about happened to those patients but,
`
`unfortunately, we have relatively little
`
`23 well-docum'=r.ted data regarding ot.her less Sf~rious
`
`24
`
`25
`
`adverse events in that cohort of 80. Other than
`
`patient diaries, we have essentially no
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 13 of 400
`
`
`
`14
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`documentation about exactly whut dose those
`
`patients took and for how long.
`
`I huve gone into this at some depth
`
`because the safety experience in the NDA is
`
`relatively small as compared to a typical NDA, and
`
`thut is by agreement. This is an orphan product.
`
`Based on the sponsor's estimated prevalence of
`
`cataplexy of about 25,000, it received orphan
`
`designation and one wouldn't necessarily expect
`
`10
`
`that a safety database of a typical size, which is
`
`11
`
`12
`
`somewhere in at least 10000 to 2000 patients in the
`
`typical NDA, would be submitted in un orphan
`
`13
`
`application. So, we agreed with the sponsor that
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`about 500 patients treated for appropriate
`
`durations, at appropriate doses would be
`
`acceptable.
`
`But, given the relatively small database
`
`and some of these residual questions about a
`
`reasonable proportion of it, that is to say Dr.
`
`Scharf's data, that may take on some additional
`
`21 meaning and we would like you to think about that
`
`22
`
`as the day goes on.
`
`23
`
`24
`
`25
`
`Ir. addition to the safety and the
`
`effectiveness data which is ~equi~ed ir. an NDA of
`
`course, tr.c sponsor has proposed a detailed risk
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 14 of 400
`
`
`
`15
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`management p~-ogram, ar..d that hu.s thre~?. goals: to
`
`inform putients and physicians about. the risks of
`
`GHB; to minimize the risks to those patients; and
`
`also to micimize the likelihood that. subjects for
`
`whom the drug has not been prescribed will be
`
`exposed to it. This latter point not only refers
`
`to diversion and its use illicitly by folks who
`
`shouldn 1 t be taking it, but also to the accidental
`
`use of GHB in the home, perhaps by small children,
`
`and you will hear how GHB is administered and what
`
`form it is prepared in, and we thir.k that is a
`
`pot.ential risk. So, we would lik~ you to think
`
`about that as the day goes on too.
`
`As far as the risk managP.ment program, you
`
`15 will hear about it in great detail from the company
`
`16
`
`but, in bri."?.f, it consists of a coup:e of sort of
`
`17 major components. One is that the product will be
`
`18
`
`made availahle through a central pharmacy and will
`
`19
`
`be shipped directly to the patient at home.
`
`20
`
`P~ysicians and patients will also receive detailed
`
`21 materia:.::; about the risks and t::-.te appropriate use
`
`22
`
`of t~c drJg after the first prcscript.io~ is filled.
`
`23 Actually, t.hey will receive tt:.os..-: materials
`
`24
`
`initially and all subsequent refi~·ls of
`
`25
`
`pre::;criptions will be contir.gent upon patients and
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 15 of 400
`
`
`
`16
`
`1
`
`physicians documenting that they have read these
`
`2 materials, und they understand the risks and how to
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`take the drug appropriately.
`
`All patients and physicians will be
`
`entered into a registry, and there will be close
`
`surveillance instituted to ensure that untoward
`
`events ar·e minimized, for example, to ensure that
`
`patients don 1 t go from doctor to doctor trying to
`
`get refills of prescriptions that are
`
`10
`
`inappropriate.
`
`11
`
`12
`
`13
`
`So, with these data and against the
`
`background of misuse of GHB out in the population
`
`at large, we bring you today's application and we
`
`14 will ask you to formally vote on three questions.
`
`15
`
`One is whether or not you think that substantial
`
`16
`
`evidence of effectiveness has been submitted for
`
`17
`
`the indications that the sponsor has proposed, that
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`is to say, cataplexy and excessive daytime
`
`sleepiness in patients with narcolepsy.
`
`If you
`
`find that they haven't, we would be very interested
`
`to know whether or not you feel that substantial
`
`evidence has been submitted fo~- either of those two
`
`indications.
`
`While you listen to the effectiveness
`
`data, we would like you to pay particular attention
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 16 of 400
`
`
`
`17
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`to the question of dose ar:.d for which dose you
`
`thir.k evidence of effectiveness has been submitted.
`
`If you find there is substantial evidence of
`
`effectiveness for a particular indication, we ~eed
`
`to ask you whether or not GHB can be considered
`
`safe in use given appropriate labe1ing. Now, we
`
`are not goi.ng to discuss necessarily the specifics
`
`of proposed labeling but, nonetheless, we ask you
`
`to think of it in that context.
`
`Again, in assessing the safety of the
`
`product, we ask you to conc~ntrate on at least the
`
`question of what dose you have found to be
`
`effective and whether or not there is sufficient
`
`safety experience at that dose for the drug to be
`
`approved.
`
`Finally, we want to tak~ a formal vote on
`
`the question of whether or not you think it is
`
`required or should be required that the drug be
`
`approved only with the risk management program of
`
`some type, not necessarily the o~c specifically
`
`proposc·d by the company. Obviously, the company
`
`has proposed a risk management program but we need
`
`to know whether or not you thir:.k it. is mandatory
`
`that it be approved with such a p!"ogram in place.·
`
`25
`
`If you do, we have a number of questions that we
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 17 of 400
`
`
`
`18
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`would like you to discuss -- not necessarily take a
`
`fo::-mal vote on but discuss with regard to a risk
`
`management program and some of the provisions that.
`
`the sponsor has proposed.
`
`There are some asp-=:cts of the prog1·am that
`
`they have proposed that we would like you to pay
`
`particular attention to and discuss. For example,
`
`there is some considerable sympathy in the agency
`
`for including a provision in the risk management
`
`10
`
`program that would restrict t.he use of the drug to
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`patients with whatever indication you believe has
`
`been supported, that is to say, to restrict as much
`
`as possible off-label presc::ibing. That is one
`
`possibility.
`
`There is also some enthusiasm internally
`
`for physicians and patients to document that they
`
`have reviewed the relevant mate;.ials before the
`
`first prescription is filled. So, we would like
`
`you to think about that as w~ll as we talk about
`
`the risk management program.
`
`So, as you can see from the agenda, the
`
`company is going to present thP. safety and
`
`effectiveness data, after ·which Dr. Mani, from the
`
`24 Division, will come up and p!.·esent briefly some of
`
`25
`
`our views about the data yo1J will have just heard.
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 18 of 400
`
`
`
`19
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`Specifically, I believe we t1avc some different
`
`views about the evidence submitted for establ ish.ir:.g
`
`a claim for excessive daytime sleepiness in
`
`narcolepsy, and there may b0. ot.her additional
`
`safety issues that we would li}:c to bring up at
`
`that time, in particular the question of an event
`
`that has been called sleep walking.
`
`I think with that as background, I will
`
`turn it back to Dr. Kawas. Thank you.
`
`10
`
`DR. KAWAS: Thank you, Dr. Katz. Orphan
`
`11 Medical presentation is to follow. Dr. David
`
`12
`
`13
`
`14
`
`Reardan, Orphan Medical?
`
`Orphan Medical Presentation
`
`DR. REARD&~: Hi. Good morning. Good
`
`15 morning, ladies and gentlemen, members of the
`
`16
`
`committee and FDA.
`
`17
`
`18
`
`[Slide]
`
`My name is ~avid Reardan, and I represent
`
`19 Orphan Medical as heud of regulatory affairs.
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Orphan Medical is a small, 60-person firm,
`
`dedicated to the developmer.t of orphan drugs. We
`
`have obtained marketing app~·oval for six orphan
`
`products from FDA since we werP. founded, in 1994.
`
`The fi!.·m became involved with Xyrem when
`
`approached by FDA thut same yeur, and Xyrem was
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 19 of 400
`
`
`
`20
`
`1
`
`2
`
`designated an orphan drug in 1994. Today we will
`
`share with you the data that ha5 been collected
`
`3 with respect to the efficacy and safety since our
`
`4
`
`.5
`
`6
`
`7
`
`8
`
`IND was submitted, in 1996 .
`
`[Slide]
`
`Dr. Mignot, direct at- of the Narcolepsy
`
`Institute at Stanford University, will present a
`
`picture of a narcoleptic patient and the serious
`
`9 medical need such patients have for new therapeutic
`
`10
`
`treatments.
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`Dr. Houghton is the chief medical officer
`
`and chief operating officer at Orphan Medical, and
`
`he will present next on thP. efficacy that has been
`
`collected. Dr. Houghton was chair of anesthesia
`
`and critical care in Australia.
`
`Dr. Black, di rer..:::tor of the Stanford Sleep
`
`17 Clinic and an investigator for several trials, will
`
`18
`
`share with you the EEG pharmacology of Xyrem. Dr.
`
`19 Houghton will then present the safety data and
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`finish up with a benefit/risk assessment.
`
`Following preser.tutions by two FDA invited
`
`speakers with respect to GEB abuse, Dr. Balster,
`
`director of the Institute for Drug and Alcohol
`
`Studies at the Medical Col~~ge of Virginia, will
`
`share with you his views o~ abuse liability.
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 20 of 400
`
`
`
`21
`
`1
`
`2
`
`Since there is public abuse of GHB and its
`
`analogs, the company has developed a risk
`
`3 management program for Xyrcm t~at will be p~esented
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`by Patti Engel, our vice president of marketing and
`
`sales.
`
`(Slide]
`
`In addition to those presenting today, the
`
`following experts are available in the audience to
`
`answer questions from the committee or FDA:
`
`D~-
`
`Emsellem, Dr. Hagaman and Dr. Ristanovic are all
`
`directors of their respective sleep institutes, and
`
`have been investigators in our clinical trials.
`
`13 Dr. Okerholm is a consultant. in the area of
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`pharmacokinetics and drug metabolism; Dr. Reno in
`
`the area of toxicology; and Dr. Richard Trout, who
`
`is a professor emeritus in statistics from Rutgers,
`
`is here if there are any statistical questions.
`
`(Slide]
`
`This is the chemical structure of sodium
`
`oxybate, more commonly known as gamma
`
`hydroxybutyrate, or GHB. Notice that it is a
`
`simple 4-carbon hydroxy fatty acid and, as such,
`
`quite easy to synthesize.
`
`In fact, kits have been
`
`illegally p::-omoted on the Internet for its
`
`25 manufacture.
`
`If an amino group were to replace
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 21 of 400
`
`
`
`22
`
`1
`
`2
`
`3
`
`•i:
`
`5
`
`6
`
`7
`
`8
`
`9
`
`this alcohol functional group at position 4, you
`
`would have GABA, gamma aminobutyric acid, anothe!""
`
`CNS active chemical. Oxybate is a natural compound
`
`in the human body.
`
`[Slide]
`
`Gamma hydroxybutyrate was first discovered
`
`in the 1960's by Dr. Labore, in France, and was
`
`investigated as an analog for GABA.
`
`It was found
`
`to have hypnotic properties and was first approved
`
`10
`
`in France, and later a few other countries of
`
`l l Europe, as an adjunct in anesthesia.
`
`It was used
`
`12
`
`1.1
`
`14
`
`IS
`
`lf'i
`
`17
`
`18
`
`19
`
`20
`
`21
`
`in labor and delivery for quite a few years. The
`
`injectable form is still available today in parts
`
`of Europe.
`
`In the 1970's initial work was begun in
`
`Canada to test its propert.ies in narcolepsy.
`
`Following initial promise for use in patients with
`
`narcolepsy two controlled trials were conducted by
`
`independent investigato~s. one in the U.S. and one
`
`in The Netherlands.
`
`In 1994, due to the promising
`
`investigator trials, FDA Off.ice of Orphan Products
`
`2~
`
`approached Orphan Medical to consider the cumpound
`
`2~'!.
`
`24
`
`2S
`
`fer development.
`
`Since there was no patent protection and
`
`the market was very small, no other firms were
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 22 of 400
`
`
`
`1 willing to consider the development of GH3 foY
`
`2
`
`3
`
`4
`
`S
`
`6
`
`7
`
`8
`
`9
`
`narcolepsy at the time. Orphan Medical agreed to
`
`sponsor this medicution. Our new drug application
`
`was submi tt.ed in October of 2000 and was designated
`
`by FDA for priority review.
`
`The clinical development has been fairly
`
`straightforward and all controlled trials ccnducted
`
`to date have shown sodium oxybate to be effective
`
`and safe for the treatment of narcolepsy. This
`
`10
`
`project has been mude more difficult becaus0 of the
`
`11
`
`12
`
`13
`
`1·1
`
`abuse situation.
`
`[Slide]
`
`Let me explain why Xyrem is not going to
`
`be a factor in the abuse of GHB and its prccur.sors.
`
`15 Orphan Medicul was aware abuse existed at the time
`
`16
`
`the company agreed to sponsor development of Xyre.m.
`
`17 At this same time, Internet was burgeoning. Due to
`
`18
`
`its ease of synthesis and ready availability ot
`
`19
`
`precursor chemicals. GHB was initially an P.asy
`
`20
`
`target for promoters of illegal drugs.
`
`But GHB is not the only problem. GRL and
`
`22
`
`23
`
`24
`
`1, 4 -butanediol are p:::-ecursor chemicals that :::an be
`
`easily converted to GHB and arc, in fact, ccnverted
`
`to GHB in the human body. These precu~·so:.s are
`
`25 widely available as bulk chemicals and are being
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 23 of 400
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`illegally used in the United States, and the abuse
`
`problem is growing.
`
`Federal legislation, enacted in 2000,
`
`helped to control the availability of GHB and GBL
`
`but not 1, 4 -b"...Itanediol and otter p:rccursor
`
`chemicals that can be used for the same purpose.
`
`In many states, even with GHB schedules, GBL and
`
`1,4-butanediol are not controlled.
`
`We believe that approval of Xyrcm for. use
`
`10
`
`by patients with narcolepsy will not add to the
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`general abuse problem of GHB and its numerous
`
`precursors.
`
`[Slide]
`
`The proposed indication for which we are
`
`asking FDA for marketing approval is to reduce the
`
`incidence of cataplexy and to improve the symptom
`
`17
`
`of daytime sleepiness in patients with narcolepsy.
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`[Slide]
`
`Narcolepsy fits the definition of orphan
`
`disease in the United States, with less than
`
`200,000 patients. There are estimated to be about
`
`135,000 patients, of which 55 percent a~e
`
`diagnosed, with about 24,000 seeking treutment for
`
`cataplexy.
`
`[Slide]
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 24 of 400
`
`
`
`25
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`B
`
`9
`
`I would now like to introduce you to Dr.
`
`Emmanuel Mignot., from Stanford. Dr. Mignot has
`
`been widely published in this area a~d is
`
`considered one of the premiere internfltionai
`
`expe~·ts on narcolepsy. He has not participated in
`
`any of our. clinical trials.
`
`Medical Need
`
`DR. MIGNOT:
`
`It is my privilege to talk to
`
`you today about narcolepsy.
`
`I have been working on
`
`10
`
`narcolepsy for about 15 years, both at the level of
`
`11
`
`basic research as well as clinical care.
`
`I am a
`
`12 medical doctor and I see patients with na~colepsy.
`
`13
`
`14
`
`[Slid"]
`
`I am going to try to summarize in a few
`
`15 minutes really a lot of data about narcolepsy and
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`how it impacts people.
`
`[Slide]
`
`First., I would like to start bl·iefly by
`
`reviewing tr.c symptoms of narcolepsy. Narcolepsy
`
`is usually associated with 5 different symptoms.
`
`The most disabling and the most problematic in
`
`patients with narcolepsy is sleepiness. Patients
`
`23 with narco~epsy are sleepy all the time; tired;
`
`24
`
`they have s:..cep attacks; they car:not. stay awake for
`
`25
`
`a long period of time, and it is usually why they
`
`PAR1003
`IPR of U.S. Patent No. 8,731,963
`Page 25 of 400
`
`
`
`26
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`come to see the doctor. They juf;t cannot live a
`
`normal life. Especially in wo~k coP.ditlons, as you
`
`probably know, it is very difficult -- you have to
`
`be awake all day long and it js a major problem in
`
`narcolepsy.
`
`Now, it is not enough to dlagcose
`
`narcolepsy. Narcolepsy is not just sleepiness and
`
`there are a lot of other medical conditions that
`
`are associated with sleepiness. Patients with
`
`10
`
`narcolepsy also have a series of symptoms that
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`correspond to the fact that they go very quickly
`
`into rapid eye movement sleep. As probably many of
`
`you know, rapid eye movement sleep is a stage of
`
`sleep that only occurs 1.5 or 2 hours after you
`
`fall asleep where you are actively dreaming but
`
`your body is completely paralyzed ar.d you have
`
`these rapid eye movements.
`
`Patients with na~-colepsy qo into REM sleep
`
`extrem~ly quickly, sometimes in a few minutes, and
`
`that leads to a series of symptoms where patients
`
`sometimes are half way thro